ArticleOrphanet journal of rare diseases2026
Patient-reported clinical characteristics and healthcare utilization in Spinal Muscular Atrophy (SMA): a cross-sectional study from Iran.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal Muscular Atrophy (SMA) is a rare, inherited neuromuscular disorder characterized by progressive muscle wasting and imposing a significant clinical and economic burden on both patients and health care systems. Although global research on SMA is expanding, limited evidence is available from low- and middle-income countries, including Iran. This study aimed to provide a comprehensive profile of patients with SMA in Iran using self-reported data, with a focus on clinical characteristics, economic burden, and patterns of healthcare utilization.
methodsA cross-sectional study was conducted among 73 patients with SMA identified through the national SMA patient advocacy association. Data were collected via structured telephone interviews using a pre-tested questionnaire covering seven domains: sociodemographic characteristics, clinical profile, and health care utilization as prescribed by physicians, direct medical and non-medical costs. Descriptive analysis was performed using SPSS (v23).
resultsAmong the 73 participants (49.3% female), the majority had SMA Type 2 (63.0%) and were older than 10 years (97.3%). Hospitalization was reported by 52.1% of patients, with SMA-related admissions incurring significantly higher costs (average costs: $240.764) and longer stays. Regarding disease-modifying therapy, 56.2% received SMN-targeted treatments. Perceived efficacy assessments revealed that 72% and 81.25% of Nusinersen and Risdiplam -treated patients reported "good or significant" clinical improvement, respectively. Outpatient service use was variable: 49.3% had never received occupational therapy, and 74.0% had not engaged in physiotherapy. General practitioner (GP) visits were more common (68.5%), while consultations with pulmonologist and cardiologist visits were infrequent (24.7% and 27.4%, respectively). Only 19.2% reported having annual preventive check-ups.
conclusionThe findings underscore considerable heterogeneity in service utilization and economic burden among patients with SMA in Iran. the underuse of rehabilitation and specialist care may reflect access barriers or financial constraints. There is a critical need for national strategies to improve early diagnosis, ensure equitable access to therapies, and integration of SMA care into existing health insurance frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.